ETON

#2103
Eton Pharmaceuticals, Inc. - Common Stock
59.9 0 USD
-0.03%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
59.90
59.90
Jahresspanne
14.27
66.37
Tagesänderung
-3.32%
Monatliche Änderung
+24.87%
6 month change
+241.70%
Jahresänderung
+231.31%
Vorheriger Schlusskurs
61.9 6
Open
59.9 0
Tief
59.9 0
Hoch
59.9 0
Volumen
163
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Eton Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Eton Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Eton Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Eton Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Eton Pharmaceuticals, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Eton Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Eton Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Eton Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Eton Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Eton Pharmaceuticals, Inc. current report, Q2 FY2026
8-K

Eton Pharmaceuticals, Inc. current report, Q1 FY2026

Full document

Eton Pharmaceuticals, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed on February 27, 2026, by Eton Pharmaceuticals, Inc. (NASDAQ: ETON). The filing discloses the entry into a material definite agreement and the completion of an asset acquisition regarding the U.S. rights to HEMANGEOL® (propranolol) oral solution.

Key Financial Metrics and Transaction Details

  • Upfront Payment: $14.0 million paid to Pierre Fabre Medicament Sas.
  • Inventory Purchase: Approximately $1.5 million at closing, with an estimated additional $0.7 million in May 2026.
  • Royalty Obligation: 8% on net sales for the duration of the product's patent life.
  • Financing: Transaction funded by cash on hand.
  • Historical Sales: 2025 sales of HEMANGEOL were $11.7 million (per IQVIA data).

The filing does not provide current period revenue, profit, cash flow, margins, debt, or liquidity metrics for Eton Pharmaceuticals, Inc. as this is a transaction-specific report rather than a periodic financial statement.

Material Changes and Operational Impact

The Company acquired U.S. rights to HEMANGEOL®, an Orphan Drug indicated for proliferating infantile hemangioma. A transition services agreement is in place where the Licensor will continue distribution until April 30, 2026, after which Eton will commercialize the product in the United States. Management expects the transaction to be accretive to 2026 earnings.

Guidance, Outlook, and Risks

Management commentary indicates an expectation of earnings accretion for 2026. The filing does not provide specific forward-looking guidance, risk factors, or contingencies beyond the standard terms of the licensing agreement and the transition period.

Key Facts for Investor Verification

  • Verify the Company's current cash balance to confirm the ability to fund the $14.0 million upfront payment and subsequent inventory purchases without external financing.
  • Confirm the specific patent expiration dates for HEMANGEOL® to assess the duration of the 8% royalty obligation.
  • Review the transition services agreement details to understand the handover process and potential risks in commercialization post-April 30, 2026.
  • Validate the $11.7 million 2025 sales figure and assess market trends for infantile hemangioma treatments.

Nachrichten